Angelini Pharma to acquire Arvelle Therapeutics in $960 million deal

pharmafile | January 6, 2021 | News story | Research and Development Angelini Pharma, central nervous system 

Angelini Pharma is set to acquire Arvelle Therapeutics, a biopharmaceutical company focused on bringing innovative treatments to patients suffering from central nervous system (CNS) disorders, in a $960 million deal.

Following the pharmaceutical company’s acquisition of Arvelle Therapeutics, Angelini Pharma will have the exclusive licence to commercialise cenobamate – used for the treatment of drug-resistant focal-onset seizures in adults – in the EU and other countries in the European Economic Area. Angelini Pharma plans to launch cenobamate after receiving approval from the EMA, which is expected in 2021.

Key study findings have documented cenobamate’s clinical efficacy by showing a significant greater reduction in median seizure frequency, and more patients achieving a 50% or greater reduction in seizure frequency, compared with the placebo group.

Cenobamate is approved in the US as an anti-seizure medication (ASM) for the treatment of partial-onset seizures in adults, and is available under the brand name XCOPRI.

Pierluigi Antonelli, CEO of Angelini Pharma, said: “We are thrilled to sign this promising agreement and are enthusiastic about the commitment and work that our colleagues at Arvelle have put into the business during the last years. We share the same patient-centric culture and agility attitude.

“This transaction will propel us into a leading European player, well positioned to address the needs of patients with different CNS disorders through an innovative portfolio, distinctive medical capabilities and extensive commercial presence, also via the opening of direct affiliates in France, UK, Nordics and Switzerland by 2022.”

Darcy Jimenez

Related Content


Angelini Pharma and JCR Pharmaceuticals partner to develop new epilepsy therapies

Angelini Pharma and JCR Pharmaceuticals have announced that they have entered into an exclusive global …

US biotech company to try resurrect the clinically dead

A US biotech firm has announced plans for a Phase I trial that will see …

Teva image

Teva buys majority stake in genomic analysis firm

Teva has agreed to by a 51% equity share of genomic-analysis company Immuneering to advance …

Latest content